Valproic acid hepatic fatalities. III. U.S. experience since 1986
- 1 February 1996
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 46 (2) , 465-469
- https://doi.org/10.1212/wnl.46.2.465
Abstract
We report the results of a third retrospective study of the U.S. experience with fatal hepatotoxicity associated with valproic acid (VPA). In the United States, over one million patients received new prescriptions for VPA during the years 1987 to 1993, and 29 patients developed fatal hepatotoxicity. Decreased alertness, jaundice, vomiting, hemorrhage, increased seizures, anorexia, and edema were the most common presenting signs. Risk factors included young age, polytherapy, developmental delay, and coincident metabolic disorders. Patients less than 2 years old receiving VPA as polytherapy were at the greatest risk (1:600) of developing this complication. NEUROLOGY 1996;46: 465-469Keywords
This publication has 7 references indexed in Scilit:
- Charles A. JanewayEuropean Journal of Pediatrics, 1994
- 18Fluorodeoxyglucose Positron Emission Tomography Studies in Presumed Alzheimer Cases, Including 13 Serial ScansCanadian Journal of Neurological Sciences, 1990
- Propranolol in the prophylaxis of oesophageal variceal haemorrhage in patients with cirrhosis: A double-blind, multicenter controlled trialJournal of Hepatology, 1990
- Distribution of Seizure Types in an Epileptic PopulationEpilepsia, 1988
- Hepatic Considerations in the Use of Antiepileptic DrugsEpilepsia, 1987
- Message from the new Editor‐in‐ChiefNeurology, 1987
- Bone Disease in Primary Biliary Cirrhosis: Increased Bone Resorption and Turnover in the Absence of Osteoporosis or OsteomalaciaHepatology, 1984